Evotec SE (EVO) Interest & Investment Income (2009 - 2023)
Evotec SE (EVO) reported Interest & Investment Income of $2701.9 for Q3 2023, down 28.66% on a YoY basis from $3787.1 in Q3 2022, and down 13.0% sequentially from $3105.6 in Q2 2023.
Evotec SE (EVO) Interest & Investment Income (2009 - 2023) Analysis & Trends
Evotec SE (EVO) has 7 years of Interest & Investment Income data on file, last reported at $2701.9 in Q3 2023.
- For the quarter ending Q3 2023, Interest & Investment Income fell 28.66% year-over-year to $2701.9; the trailing twelve-month figure through Sep 2023 stood at $8.5 million (up 226.85% YoY), and the FY2022 full-year result was $8.5 million, up 227.22% from the prior year.
- Interest & Investment Income slipped to $2701.9 in Q3 2023, from $3105.6 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $8.5 million in Q4 2022 to a low of -$1059.4 in Q3 2020.
- A 5-year average of $1.2 million and a median of $2701.9 in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income plunged 35.43% in 2020 and surged 404.13% in 2022, its largest moves.
- Tracing EVO's Interest & Investment Income over 5 years: stood at $2.5 million in 2019, then sank by 35.43% to $1.6 million in 2020, then soared by 62.82% to $2.6 million in 2021, then surged by 227.23% to $8.5 million in 2022, then slumped by 99.97% to $2701.9 in 2023.
- Business Quant data shows EVO's Interest & Investment Income at $2701.9 in Q3 2023, $3105.6 in Q2 2023, and $8.5 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Evotec SE | 339.17 Mn | 338.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 2,701.88 |
| Jun 30, 2023 | 3,105.61 |
| Dec 31, 2022 | 8.50 Mn |
| Sep 30, 2022 | 3,787.08 |
| Jun 30, 2022 | 1,314.61 |
| Mar 31, 2022 | 885.52 |
| Dec 31, 2021 | 2.60 Mn |
| Sep 30, 2021 | 751.21 |
| Jun 30, 2021 | 649.10 |
| Mar 31, 2021 | 605.53 |
| Dec 31, 2020 | 1.60 Mn |
| Sep 30, 2020 | -1,059.45 |
| Dec 31, 2019 | 2.47 Mn |
| Sep 30, 2010 | 34.86 |
| Jun 30, 2010 | 82.86 |
| Mar 31, 2010 | 116.32 |
| Dec 31, 2009 | 736,248.00 |
| Jun 30, 2009 | 156.59 |
| Mar 31, 2009 | 323.01 |